Evidence map›Paper›PMID 23728174›Full record

Trial reportThe Journal of clinical investigation2013

Exenatide and the treatment of patients with Parkinson's disease.

Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees and 2 more

4 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 271 papers, 20 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
271citing papers in PubMed, 20 pooled it
26.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01174810 phase2unknown statusnot on this map

An Open Label, Single Site, 12 Month, Phase II, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exendin-4 (Exenatide) in the Treatment of Patients With Moderate Severity Parkinson's Disease.

TypeinterventionalSponsorUniversity College, LondonRan2010 to 2013Enrolled40ConditionsParkinson's DiseaseArmsExenatide
NCT02847403 phase3unknown statusnot on this mapstarted 2016, after this paper: background citation

Long-acting Exenatide: a Tool to Stop Cognitive Decline in Dysglycemic Patients With Mild Cognitive Impairment?

TypeinterventionalSponsorAzienda Ospedaliero-Universitaria di ParmaRan2016 to 2021Enrolled40ConditionsDysglycemia, Cognitive DeficitArmsExenatide, placebo
NCT03840005 phase2completednot on this mapstarted 2018, after this paper: background citation

A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial To Assess The Safety And Tolerability Of 30mg/kg Daily Ursodeoxycholic Acid (UDCA) In Patients With Parkinson's Disease (PD)

TypeinterventionalSponsorSheffield Teaching Hospitals NHS Foundation TrustRan2018 to 2021Enrolled31ConditionsParkinson's DiseaseArmsUrsonorm
NCT04431713 phase2completednot on this mapstarted 2020, after this paper: background citation

An Open Label, Single Site, 48 Week, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exenatide Once-weekly in the Treatment of Patients With Multiple System Atrophy

TypeinterventionalSponsorUniversity College, LondonRan2020 to 2024Enrolled50ConditionsMultiple System AtrophyArmsExenatide Pen Injector [Bydureon]
3 · Its place in the literature

Who cites it

271 citing papers in PubMed, 20 syntheses or guidelines pooled it, 500 citations in OpenAlex.

  1. Pooled it
  2. Glucagon-like peptide-1 agonists in Parkinson's disease: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  3. Pooled it
  4. Efficacy of GLP-1 receptor agonists in Parkinson's disease: a systematic review and exploratory network meta-analysis of randomized controlled trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Evaluating the neuroprotective effect of GLP-1 receptor agonists in parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Pooled it
  8. From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson's disease. A systematic review and meta-analysis of placebo-controlled trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Do oral antidiabetic medications alter the risk of Parkinson's disease? An updated systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023 · on this map
    Pooled it
  17. Pooled it
  18. Pooled it
  19. GLP-1 receptor agonists for Parkinson's disease.The Cochrane database of systematic reviews · 2020
    Pooled it
  20. Antidiabetic Agents for Treatment of Parkinson's Disease: A Meta-Analysis.International journal of environmental research and public health · 2020
    Pooled it

211 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Iciar Aviles-OlmosSobell Department of Motor Neuroscience, UCL Institute of Neurology, London, United Kingdom.
John Dickson
Zinovia Kefalopoulou
Atbin Djamshidian
Peter Ell
Therese Soderlund
Peter Whitton
Richard Wyse
Tom Isaacs
Andrew Lees
Patricia Limousin
Thomas Foltynie
University College London · GBSobell House · GBUniversity College London Hospitals NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledBACKGROUND. There is increasing interest in methods to more rapidly and cost-efficiently investigate drugs that are approved for clinical use in the treatment of another condition. Exenatide is a type 2 diabetes treatment that has been shown to have neuroprotective/neurorestorative properties in preclinical models of neurodegeneration. METHODS. As a proof of concept, using a single-blind trial design, we evaluated the progress of 45 patients with moderate Parkinson's disease (PD), randomly assigned to receive subcutaneous exenatide injection for 12 months or to act as controls. Their PD was compared after overnight withdrawal of conventional PD medication using blinded video assessment of the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), together with several nonmotor tests, at baseline, 6 months, and 12 months and after a further 2-month washout period (14 months). RESULTS. Exenatide was well tolerated, although weight loss was common and l-dopa dose failures occurred in a single patient. Single-blinded rating of the exenatide group suggested clinically relevant improvements in PD across motor and cognitive measures compared with the control group. Exenatide-treated patients had a mean improvement at 12 months on the MDS-UPDRS of 2.7 points, compared with mean decline of 2.2 points in control patients (P = 0.037). CONCLUSION. These results demonstrate a potential cost-efficient approach through which preliminary clinical data of possible biological effects are obtainable, prior to undertaking the major investment required for double-blind trials of a potential disease-modifying drug in PD.

trial registrationClinicaltrials.gov NCT01174810.

fundingCure Parkinson's Trust.

Indexed as

AgedAntiparkinson AgentsConstipationDisease ProgressionDrug RepositioningExenatideFemaleHumansHypoglycemic AgentsInjections, SubcutaneousMaleMiddle AgedMotor ActivityOff-Label UseParkinson DiseasePeptidesAntiparkinson AgentsExenatideHypoglycemic AgentsPeptidesVenoms

Identifiers

PMID23728174
PMCPMC3668846
OpenAlexW2123319002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.